Champions Oncology (NASDAQ:CSBR) shares fell 23% in a month, yet surged 47% in a year. The company transitioned from loss to profit, showing growth potential. Revenue growth of 19% and modest CEO pay suggest a positive outlook.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing